GSK's revenue and EPS exceeded my expectations and those of analysts. Check out the reasons why I am upgrading GSK stock's ...

GSK, a UK-based biopharma, reported strong 2024 results, with a promising shift toward specialty medicines. Read why I ...

GSK (LON:GSK) has raised its long-term revenue outlook, now expecting sales to exceed 40 billion by 2031, up from 38 billion. The revision reflects confidence in its expanding specialty medicines ...

Strong full-year trading and an improving outlook have propelled GSK’s share price higher, as Royston Wild explains. The content of this article is provided for information purposes only and is ...

The SWIFT-1 and SWIFT-2 trials demonstrated that depemokimab, as an add-on therapy, significantly reduced exacerbation and hospitalization rates in patients with type 2 inflammation asthma.

GSK plc has announced that new drug applications have been accepted for review by the China National Medical Products Administration and submitted to the Japanese Ministry of Health, Labour and ...

London: GSK plc has announced that the European Medicines Agency (EMA) has accepted for review the Marketing Authorisation Application for the use of depemokimab in two indications. The submitted ...

GSK plc GSK recently announced that EMA has accepted the regulatory filing seeking approval for its IL-5 inhibitor depemokimab in two respiratory indications – asthma with type II inflammation ...

GSK plc announced that the European Medicines Agency has accepted for review the Marketing Authorisation Application for the use of depemokimab in two indications. The submitted indications are for ...